Verrica Pharmaceuticals Inc. has announced new data from its Phase 2 clinical trial evaluating VP-315 (ruxotemitide), a novel oncolytic peptide immunotherapy for basal cell carcinoma $(BCC)$. The results were presented at the 40th Annual Meeting of the Society for Immunotherapy of Cancer, held November 5-9, 2025. Findings from the exploratory analysis indicate that VP-315 reprograms the tumor microenvironment by increasing cytotoxic T-cell infiltration and reducing immunosuppressive regulatory T-cells. The data also show a 97% calculated objective response rate and a 51% complete histologic clearance rate. VP-315 is administered intratumorally and is being developed as a potential first-in-class, non-surgical immunotherapeutic option for patients with BCC.